Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor

Cao, Najing; Cai, Yanxing; Huang, Xin

doi:10.1128/mbio.00741-24

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Cao, N., Cai, Y., & Huang, X. Inhibition of influenza a virus and sars-cov-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor. mBio, e00741–24.
Added by: Dr. Enrique Feoli (10/04/2024, 17:33) Last edited by: Dr. Enrique Feoli (10/04/2024, 17:45)

Resource type: Journal Article
Published
DOI: 10.1128/mbio.00741-24
BibTeX citation key: Cao
View all bibliographic details

Categories: BioAcyl Corp
Subcategories: COVID-19
Keywords: ,
Creators: Cai, Cao, Huang
Collection: mBio

Views: 18/1380

Abstract

Influenza and COVID-19 are highly contagious respiratory illnesses caused by the influenza A virus (IAV) and SARS-CoV-2, respectively. IAV and SARS-CoV-2 co-infection exacerbates damage to lung tissue and leads to more severe clinical symptoms, thus calling for the development of broad-spectrum antivirals for combating IAV and SARS-CoV-2 infection or co-infection. Here we found that griffithsin (GRFT), a carbohydrate-binding protein, and GL25E, a recombinant protein consisting of GRFT, a 25 amino acid linker, and EK1, a broad-spectrum coronavirus inhibitor, could effectively inhibit IAV and SARS-CoV-2 infection and co-infection by targeting glycans on HA of IAV and spike (S) protein of SARS-CoV-2. GL25E is more effective than GRFT because GL25E can also interact with the HR1 domain in SARS-CoV-2 S protein. Furthermore, GL25E possesses favorable safety and stability profiles, suggesting that it is a promising candidate for development as a drug to prevent and treat IAV and SARS-CoV-2 infection or co-infection.

Schematic illustration of the mechanism by which GRFT and GL25E inhibit mono- or co-infection of IAV and SARS-CoV-2. GRFT or GRFT part in GL25E binds to the glycans on HA1 of IAV, thereby inhibiting IAV entry into the host cell. GL25E inhibits SARS-CoV-2 infection by binding via its GRFT part to glycans on S1 subunit of SARS-CoV-2 S protein and interacting via its EK1 part with HR1 domain in S2 subunit of SARS-CoV-2 S protein. GRFT (PDB code: 7RID).